Drug · Small Molecule

Aminoglutethimide

CI-DRUG-00000053Explore in graph →NCIt C233 CHEMBL488 CIViC Approved

Regulatory

Approvals (1)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CYTADREN TAB 250MG (DIN 00587729) under ATC L02BG01 AMINOGLUTHETIMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 4, 1999	Dec 31, 1983	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 15 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Withdrawn	Phase 2	0	0	0	1	1	CA	—	2000-05
Malignant Prostate Neoplasm	Phase2	Phase 2	0	0	0	1	0	—	—	2000-05

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TFF3 EXPRESSION1
Aminoglutethimide + Tamoxifen

Clinical trials

Trials with this intervention (1)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–1 of 1 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00006371	A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer	terminated	Phase 2	2	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Sep 27, 2012	clinicaltrials

Molecule

Record

Kind: Small Molecule
Mechanism: Cytochrome P450 19A1 inhibitor; Cytochrome P450 11A1 inhibitor
Targets: 2 genes
Aliases: 2-(p-Aminophenyl)-2-ethylglutarimide, 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione, 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine, Alpha-(4-Aminophenyl)-alpha-ethylglutarimide, Aminoblastin, Aminoglutethimide, Aminoglutetimida, BA-16038, Cytadren, Elipten, Mamomit, NSC-330915, Orimenten, Orimeten, Orimetene, Rodazol

Data updated 11 hours agoSource updated unknown

Identifiers

Codes (3)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L02BG01	AMINOGLUTHETIMIDE
DIN (Health Canada)	00587729	CYTADREN TAB 250MG
DPD drug code